Romidepsin-associated cardiac toxicity and ECG changes: A case report and review of the literature

Background Romidepsin is a novel histone deacetylase inhibitor that is approved for the treatment of cutaneous and peripheral T-cell lymphoma in patients who have had at least one prior therapy. Romidepsin is generally well tolerated, though it comes with a risk of cardiac toxicities. Objective We r...

Full description

Saved in:
Bibliographic Details
Published in:Journal of oncology pharmacy practice 2018-01, Vol.24 (1), p.56-62
Main Authors: Rivers, Zachary T, Oostra, Drew R, Westholder, James S, Vercellotti, Gregory M
Format: Article
Language:English
Subjects:
Case reports
Chromatin
EKG
Heart
Heart diseases
Hematopoietic stem cells
Histone deacetylase
Inhibitors
Literature reviews
Lymphocytes T
Lymphoma
Peripheral blood
Salvage
Side effects
T-cell lymphoma
Toxicity
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background Romidepsin is a novel histone deacetylase inhibitor that is approved for the treatment of cutaneous and peripheral T-cell lymphoma in patients who have had at least one prior therapy. Romidepsin is generally well tolerated, though it comes with a risk of cardiac toxicities. Objective We report a case of electrocardiogram changes in a 64-year-old male with enteropathy-associated T-cell lymphoma, type 2, treated with salvage romidepsin therapy who relapsed after non-myeloablative allogeneic sibling peripheral blood stem cell transplant. Discussion Although histone deacetylase inhibitors have been investigated for many years, they have only recently been translated to clinical use as a therapy for malignancies. Furthermore, given their approval for a rare disease, clinicians often have limited experience with the dosing and side effects of histone deacetylase inhibitors. Conclusion This case report and literature review investigates the cardiac side effects of histone deacetylase inhibitors and illustrates the importance of cardiac monitoring prior to and during treatment.
ISSN:1078-1552
1477-092X
DOI:10.1177/1078155216673229